The 5th Annual Preclinical Oncology Drug Discovery Symposium will be held in Cambridge, UK
(San Diego, Calif., Mar 07 2019) — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, renews its annual appointment with oncology drug discovery researchers by hosting a symposium at the Babraham Research Campus in Cambridge, UK on March 12th 2019.
The meeting titled “Oncology Drug Discovery: Novel Perspectives and the Immuno-Oncology Generation” is part of CrownBio’s renowned series of annual events bringing together thought leaders in the field.
This year’s symposium will focus on the most recent developments in cancer treatment, including the latest insights from immuno-oncology, which are expected to enter clinical trials, and will discuss how preclinical models can support clinical decisions and maximize the value of novel anticancer drugs.
“As a thought leader in oncology drug discovery, CrownBio continues to make significant investments to improving communication among the scientific community about end-to-end preclinical to clinical service platforms” commented Dr. Rajendra Kumari Global Head of Scientific Communications. “We are excited to host this event again which attracts scientists from both industry and academia”.
The Company has assembled a notable line-up of eight industry experts, including Dr. Rob Vries, Executive Director, Hubrecht Organoid Technology (HUB) who will present data on the translatability of organoid technology to patient applications. Additionally, topics for discussion will include understanding the interplay between tumor and immune system, re-evaluating the role of well-established signaling pathways in immune modulation, as well as addressing the role of preclinical models in drug discovery.
The symposium will feature CrownBio’s Dr Davy Ouyang Executive Director, Cancer Pharmacology Global Scientific Research & Innovation, presenting the latest data on the application of humanized target models for novel immunotherapeutics.
The event is free to attend, but there are a limited number of places. To view the agenda visit: www.crownbio.com/cambridge
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
marketing@crownbio.com
